Product Review

Product Update: Kyleena; LapCap2


 

NEW LNG IUS: GOOD FOR 5 YEARS

Kyleena™ (levonorgestrel-releasing intrauterine system; IUS) 19.5 mg, from Bayer, is a new hormonal contraceptive device used to prevent pregnancy for up to 5 years. The small, flexible plastic, T-shaped long-acting reversible contraceptive can be distinguished from other IUSs by the combination of the visibility of the silver ring on ultrasound and the blue color of the removal threads, says Bayer. Kyleena is placed by a health care provider during an office visit. Bayer indicates that metrorrhagia or menorrhagia may occur during the first 3 to 6 months of use, and menstrual periods may become infrequent or cease.

FOR MORE INFORMATION, VISIT:
https://hcp.kyleena-us.com/

EASIER LAPAROSCOPIC ACCESS

LapCap2 is a sterile, single-use device with a molded plastic dome, a suction-system port, and a septum for Veress needle insertion from Life Care Medical Devices that is designed to provide safe and rapid access for minimally invasive surgery. Life Care says single-operator access and abdominal stabilization are advantages of LapCap2.

To use LapCap2, says Life Care, center it over the umbilicus, attach a hose to the suction port, and apply negative pressure. The abdomen immediately rises for Veress needle insertion. Inert gas is then delivered to replace the negative pressure, and the procedure can continue.

FOR MORE INFORMATION, VISIT:
http://www.lcmd.com/products/lapcap2

Recommended Reading

No rise in complications with concomitant gynecologic cancer, PFD surgery
MDedge ObGyn
PARP inhibitor prolongs PFS in ovarian cancer patients with and without BRCA mutations
MDedge ObGyn
Registry helps track pelvic organ prolapse outcomes in the U.S.
MDedge ObGyn
When is it time to stop hormone therapy?
MDedge ObGyn
Novel fractional laser eased genitourinary syndrome of menopause
MDedge ObGyn
Unexplained subfertility in RA linked to periconceptional NSAID use
MDedge ObGyn
Psychological stress did not harm IVF outcomes
MDedge ObGyn
CMS offering educational webinars on MACRA
MDedge ObGyn
Resveratrol cut androgen levels in small PCOS trial
MDedge ObGyn
Subgroup may benefit from seribantumab for platinum-resistant ovarian cancer
MDedge ObGyn